This study is the Company’s first reported results demonstrating that the anti-HER2 nanoparticles used in Imagion’s Magsense™ technology, which provide specific targeting of cancerous cells, may also have potential as an MR imaging contrast agent. The study shows MagSense nanoparticles may be equally effective as a multi-modal molecular imaging agint, generating detectable signals in two different imaging methods — superparamagnetic relaxometry (SPMR) and magnetic resonance imaging (MRI).
Download the poster.
[White Paper] Molecular Imaging: Changing the Way We Look at Cancer
June 1, 2023
Australasian Biotechnology | Vol 33 Number 1 Imagion authored a white paper, published in the April issue of Australasian Biotechnology, discussing current medical imaging technologies,